Stockrabit · Analysts
Questions across 2 calls

Sidharth Negandhi

Firm not listed in source transcripts

Biocon Limited

Biocon Limited CC-May26.pdf · 2026-05-08
This is Sidharth Negandhi from CWC. A couple of questions. One, could you give us an understanding of the constant currency sales in each of the divisions? The second one was if you could give us some colour in terms of market shares and the $200 million benchmark that you had shared last year. If you could give us an update on both of those, the market shares as well as the number of products that are above $200 million in biosimilars.
Great. And Kedar, if you could also help with any update on the market shares that you had shared last year. And the margin improvement that we are seeing in the generics business adjusted for Revlimid, I just wanted to understand, is that a function of t he change in the API and formulation mix or is there something else?
Biocon Limited CC-Nov25.pdf · 2025-11-12
Hi, this is Sidharth Negandhi from CWC. Firstly, congratulations on a very strong set of numbers and an improved balance sheet. I had two questions. First, there have been certain formularies that have excluded Aspart as a class. And in certain cases where NovoLog is at a superior tier to Kirsty. How do we look at sales for Kirsty and for Aspart in that case going forward? That was question number one. Question number two was given the upcoming patent cliffs and specifically on Keytruda, which is really the largest one. There is no record of any clinical trials ongoing for Biocon. So, is that going on through a partnership? How should we think of your pa rticipation in biosimilar Keytruda? That was question number two
Sure. Matt, just wanted to understand given that it is the top 2 formularies, Optum Rx, premium formulary and the Express Scripts, which have, in one case, excluded Aspart as a class itself, does that, in any way, inhibit or limit the TAM for Aspart?